Partnering Deals and Alliances with Big Pharma

NEW YORK, Oct. 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Partnering Deals and Alliances with Big Pharma
http://www.reportlinker.com/p01524244/Partnering-Deals-and-Alliances-with-Big-Pharma.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.

Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.

This premier report provides all the information you require to better understand big pharma partnering.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives. Over 300 charts allow quick understanding of each big pharma companies dealmaking trends over the last four years.

This report contains over 3,000 links to online copies of actual partnering deals as recorded at Current Agreement, together with contract documents if submitted to the Securities Exchange Commission by bigpharma and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of bigpharma's dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big pharma companies based on 2012 pharmaceutical revenues and dealmaking activity since 2007.

Chapter 3 reviews the top partnering and M&A deals of 2007-2013 according to reported deal size.

Chapter 4 provides a summary on best practice on how to submit an opportunity to big pharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 5 lists forthcoming partnering events where valuable face to face meetings with big pharma provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 6. In-depth profiles of every big pharma company provide everything required to assess the suitability of a company as a prospective partner. Each profile includes a company overview, partnering activity according to deal type, phase of development, therapy area and technology type.

Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partners' negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This data driven report contains over 3,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In addition, contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In summary, the report provides the reader with the tools necessary to make successful contact with the right big pharma partners effectively and efficiently.

Key benefits

Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big pharma companies
Over 300 charts showing a company's dealmaking activity since 2007, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2007 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Partnering Deals and Alliances with Big Pharma is intended to provide the reader with an in-depth understanding of the partnering activities of the leading fifty big pharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company's partnering.

Partnering Deals and Alliances with Big Pharma includes:

Detailed company profiles for each of the top 50 big pharma companies, including:
Partnering interests and indications
Partnering activity since 2007
Partner companies since 2007
Partnering activity since 2007 by:
Partner company
Deal type
Industry sector
Stage of development
Technology type
Therapy area
Over 300 charts showing the dealmaking activity of each company since 2007
The tools to enable effective and efficient preparation for partnering negotiation with big pharma
3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
The leading M&A and partnering deals by value 2007-2013

The Partnering Deals and Alliances with Big Pharma report also provides comprehensive access to available contract documents for each of the fifty big pharma companies.

Analyzing actual company agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subscontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Executive Summary

Chapter 1 – Introduction

Chapter 2 – Big pharma top 50 dealmaking activity
2.1. Introduction
2.2. Big pharma partnering over the years
2.4. Big pharma partnering by deal type
2.5. Big pharma partnering industry sector
2.6. Big pharma partnering by stage of development
2.7. Big pharma partnering by technology type
2.8. Big pharma partnering by therapy area
2.9. Big pharma M&A over the years

Chapter 3 – Top big pharma deals by value
3.1. Introduction
3.2. Big pharma partnering
3.3. Big pharma M&A

Chapter 4 – Submitting Opportunities to Big pharma

4.1. How to submit an opportunity
4.2. Opportunity submission template
4.3. Sending emails
4.4. Face to face at partnering events
4.5. Online submission forms

Chapter 5 – Forthcoming big pharma partnering events

5.1. Forthcoming events

Chapter 6 – Big pharma Company Profiles

6.1. Introduction
6.2. Field definitions
6.3. Company profiles
Abbott
Actavis Inc.( formerly Watson)
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Fresenius
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols

Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Ranbaxy Laboratories
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Valeant
Warner Chilcott

Chapter 7 – Resources

Appendices

Appendix 1 – Deal type definitions
Appendix 2 – Example contract document
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

Table of Figures

Figure 1: Big pharma partnering 2007-2013
Figure 2: Big pharma – top 50 partnering activity 2007 to 2013
Figure 3: Big pharma deal frequency – 2007 to 2013
Figure 4: Big pharma partnering by deal type 2007-2013
Figure 5: Big pharma partnering by industry sector 2007-2013
Figure 6: Big pharma partnering by stage of development 2007-2013
Figure 7: Big pharma partnering by technology type 2007-2013
Figure 8: Big pharma partnering by therapy area 2007-2013
Figure 9: Big pharma M&A 2007-2013
Figure 10: Big pharma – top 50 M&A activity 2005-2013
Figure 11: Big pharma M&A deal frequency 2007-2013
Figure 12: Leading partnering deals by value, 2007-2013
Figure 13: Leading M&A deals involving big pharma by value, 2007-2013
Figure 14: Typical partnering opportunity submission template
Figure 15: Company profile template and definitions used in report
Figure 16: Abbott: Dealmaking frequency 2007-2013
Figure 17: Abbott: Partnering deals by type
Figure 18: Abbott: Partnering deals by industry sector
Figure 19: Abbott: Partnering deals by technology type
Figure 20: Abbott: Partnering deals by stage of development
Figure 21: Abbott: Partnering deals by therapy area
Figure 22: Actavis and Watson: Dealmaking frequency 2007-2013
Figure 23: Actavis and Watson: Partnering deals by type
Figure 24: Actavis and Watson: Partnering deals by industry sector
Figure 25: Actavis and Watson: Partnering deals by technology type
Figure 26: Actavis and Watson: Partnering deals by stage of development
Figure 27: Actavis and Watson: Partnering deals by therapy area

Figure 28: Allergan: Dealmaking frequency 2007-2013
Figure 29: Allergan: Partnering deals by type
Figure 30: Allergan: Partnering deals by industry sector
Figure 31: Allergan: Partnering deals by technology type
Figure 32: Allergan: Partnering deals by stage of development
Figure 33: Allergan: Partnering deals by therapy area
Figure 34: Amgen: Dealmaking frequency 2007-2013
Figure 35: Amgen: Partnering deals by type
Figure 36: Amgen: Partnering deals by industry sector
Figure 37: Amgen: Partnering deals by technology type
Figure 38: Amgen: Partnering deals by stage of development
Figure 39: Amgen: Partnering deals by therapy area
Figure 40: Astellas: Dealmaking frequency 2007-2013
Figure 41: Astellas: Partnering deals by type
Figure 42: Astellas: Partnering deals by industry sector
Figure 43: Astellas: Partnering deals by technology type
Figure 44: Astellas: Partnering deals by stage of development
Figure 45: Astellas: Partnering deals by therapy area
Figure 46: AstraZeneca: Dealmaking frequency 2007-2013
Figure 47: AstraZeneca: Partnering deals by type
Figure 48: AstraZeneca: Partnering deals by industry sector
Figure 49: AstraZeneca: Partnering deals by technology type
Figure 50: AstraZeneca: Partnering deals by stage of development
Figure 51: AstraZeneca: Partnering deals by therapy area
Figure 52: Baxter: frequency 2007-2013
Figure 53: Baxter: Partnering deals by type

Figure 54: Baxter: Partnering deals by industry sector
Figure 55: Baxter: Partnering deals by technology type
Figure 56: Baxter: Partnering deals by stage of development
Figure 57: Baxter: Partnering deals by therapy area
Figure 58: Bayer: Dealmaking frequency 2007-2013
Figure 59: Bayer: Partnering deals by type
Figure 60: Bayer: Partnering deals by industry sector
Figure 61: Bayer: Partnering deals by technology type
Figure 62: Bayer: Partnering deals by stage of development
Figure 63: Bayer: Partnering deals by therapy area
Figure 64: Biogen Idec: Dealmaking frequency 2007-2013
Figure 65: Biogen Idec: Partnering deals by type
Figure 66: Biogen Idec: Partnering deals by industry sector
Figure 67: Biogen Idec: Partnering deals by technology type
Figure 68: Biogen Idec: Partnering deals by stage of development
Figure 69: Biogen Idec: Partnering deals by therapy area
Figure 70: Boehringer Ingelheim: Dealmaking frequency 2007-2013
Figure 71: Boehringer Ingelheim: Partnering deals by type
Figure 72: Boehringer Ingelheim: Partnering deals by industry sector
Figure 73: Boehringer Ingelheim: Partnering deals by technology type
Figure 74: Boehringer Ingelheim: Partnering deals by stage of development
Figure 75: Boehringer Ingelheim: Partnering deals by therapy area
Figure 76: Bristol-Myers Squibb: Dealmaking frequency 2007-2013
Figure 77: Bristol-Myers Squibb: Partnering deals by type
Figure 78: Bristol-Myers Squibb: Partnering deals by industry sector
Figure 79: Bristol-Myers Squibb: Partnering deals by technology type
Figure 80: Bristol-Myers Squibb: Partnering deals by stage of development
Figure 81: Bristol-Myers Squibb: Partnering deals by therapy area
Figure 82: Celgene: Dealmaking frequency 2007-2013
Figure 83: Celgene: Partnering deals by type
Figure 84: Celgene: Partnering deals by industry sector
Figure 85: Celgene: Partnering deals by technology type
Figure 86: Celgene: Partnering deals by stage of development
Figure 87: Celgene: Partnering deals by therapy area
Figure 88: CSL: Dealmaking frequency 2007-2013
Figure 89: CSL: Partnering deals by type
Figure 90: CSL: Partnering deals by industry sector
Figure 91: CSL: Partnering deals by technology type
Figure 92: CSL: Partnering deals by stage of development
Figure 93: CSL: Partnering deals by therapy area
Figure 94: Daiichi Sankyo: Dealmaking frequency 2007-2013
Figure 95: Daiichi Sankyo: Partnering deals by type

Figure 96: Daiichi Sankyo: Partnering deals by industry sector
Figure 97: Daiichi Sankyo: Partnering deals by technology type
Figure 98: Daiichi Sankyo: Partnering deals by stage of development
Figure 99: Daiichi Sankyo: Partnering deals by therapy area
Figure 100: Dainippon Sumitomo: Dealmaking frequency 2007-2013
Figure 101: Dainippon Sumitomo: Partnering deals by type
Figure 102: Dainippon Sumitomo: Partnering deals by industry sector
Figure 103: Dainippon Sumitomo: Partnering deals by technology type
Figure 104: Dainippon Sumitomo: Partnering deals by stage of development
Figure 105: Dainippon Sumitomo: Partnering deals by therapy area
Figure 106: Eisai: Dealmaking frequency 2007-2013
Figure 107: Eisai: Partnering deals by type
Figure 108: Eisai: Partnering deals by industry sector
Figure 109: Eisai: Partnering deals by technology type
Figure 110: Eisai: Partnering deals by stage of development
Figure 111: Eisai: Partnering deals by therapy area
Figure 112: Eli Lilly: Dealmaking frequency 2007-2013
Figure 113: Eli Lilly: Partnering deals by type
Figure 114: Eli Lilly: Partnering deals by industry sector
Figure 115: Eli Lilly: Partnering deals by technology type
Figure 116: Eli Lilly: Partnering deals by stage of development
Figure 117: Eli Lilly: Partnering deals by therapy area
Figure 118: Endo Pharmaceuticals: Dealmaking frequency 2007-2013
Figure 119: Endo Pharmaceuticals: Partnering deals by type
Figure 120: Endo Pharmaceuticals: Partnering deals by industry sector
Figure 121: Endo Pharmaceuticals: Partnering deals by technology type
Figure 122: Endo Pharmaceuticals: Partnering deals by stage of development
Figure 123: Endo Pharmaceuticals: Partnering deals by therapy area
Figure 124: Forest Laboratories: Dealmaking frequency 2007-2013
Figure 125: Forest Laboratories: Partnering deals by type
Figure 126: Forest Laboratories: Partnering deals by industry sector
Figure 127: Forest Laboratories: Partnering deals by technology type
Figure 128: Forest Laboratories: Partnering deals by stage of development

Figure 129: Forest Laboratories: Partnering deals by therapy area
Figure 130: Fresenius: Dealmaking frequency 2007-2013
Figure 131: Fresenius: Partnering deals by type
Figure 132: Fresenius: Partnering deals by industry sector
Figure 133: Fresenius: Partnering deals by technology type
Figure 134: Fresenius: Partnering deals by stage of development
Figure 135: Fresenius: Partnering deals by therapy area
Figure 136: Galderma: Dealmaking frequency 2007-2013
Figure 137: Galderma: Partnering deals by type
Figure 138: Galderma: Partnering deals by industry sector
Figure 139: Galderma: Partnering deals by technology type
Figure 140: Galderma: Partnering deals by stage of development
Figure 141: Galderma: Partnering deals by therapy area
Figure 142: Gilead Sciences: Dealmaking frequency 2007-2013
Figure 143: Gilead Sciences: Partnering deals by type
Figure 144: Gilead Sciences: Partnering deals by industry sector
Figure 145: Gilead Sciences: Partnering deals by technology type
Figure 146: Gilead Sciences: Partnering deals by stage of development
Figure 147: Gilead Sciences: Partnering deals by therapy area
Figure 148: GlaxoSmithKline: Dealmaking frequency 2007-2013
Figure 149: GlaxoSmithKline: Partnering deals by type
Figure 150: GlaxoSmithKline: Partnering deals by industry sector
Figure 151: GlaxoSmithKline: Partnering deals by technology type
Figure 152: GlaxoSmithKline: Partnering deals by stage of development
Figure 153: GlaxoSmithKline: Partnering deals by therapy area
Figure 154: Grifols: Dealmaking frequency 2007-2013
Figure 155: Grifols: Partnering deals by type
Figure 156: Grifols: Partnering deals by industry sector
Figure 157: Grifols: Partnering deals by technology type
Figure 158: Grifols: Partnering deals by stage of development
Figure 159: Grifols: Partnering deals by therapy area
Figure 160: Hospira: Dealmaking frequency 2007-2013
Figure 161: Hospira: Partnering deals by type
Figure 162: Hospira: Partnering deals by industry sector
Figure 163: Hospira: Partnering deals by technology type
Figure 164: Hospira: Partnering deals by stage of development
Figure 165: Hospira: Partnering deals by therapy area
Figure 166: Johnson & Johnson: Dealmaking frequency 2007-2013
Figure 167: Johnson & Johnson: Partnering deals by type
Figure 168: Johnson & Johnson: Partnering deals by industry sector
Figure 169: Johnson & Johnson: Partnering deals by technology type
Figure 170: Johnson & Johnson: Partnering deals by stage of development
Figure 171: Johnson & Johnson: Partnering deals by therapy area

Figure 172: Kyowa Hakko Kirin: Dealmaking frequency 2007-2013
Figure 173: Kyowa Hakko Kirin: Partnering deals by type
Figure 174: Kyowa Hakko Kirin: Partnering deals by industry sector
Figure 175: Kyowa Hakko Kirin: Partnering deals by technology type
Figure 176: Kyowa Hakko Kirin: Partnering deals by stage of development
Figure 177: Kyowa Hakko Kirin: Partnering deals by therapy area
Figure 178: Lundbeck: Dealmaking frequency 2007-2013
Figure 179: Lundbeck: Partnering deals by type
Figure 180: Lundbeck: Partnering deals by industry sector
Figure 181: Lundbeck: Partnering deals by technology type
Figure 182: Lundbeck: Partnering deals by stage of development
Figure 183: Lundbeck: Partnering deals by therapy area
Figure 184: Menarini: Dealmaking frequency 2007-2013
Figure 185: Menarini: Partnering deals by type
Figure 186: Menarini: Partnering deals by industry sector
Figure 187: Menarini: Partnering deals by technology type
Figure 188: Menarini: Partnering deals by stage of development
Figure 189: Menarini: Partnering deals by therapy area
Figure 190: Merck & Co.: Dealmaking frequency 2007-2013
Figure 191: Merck & Co.: Partnering deals by type
Figure 192: Merck & Co.: Partnering deals by industry sector
Figure 193: Merck & Co.: Partnering deals by technology type
Figure 194: Merck & Co.: Partnering deals by stage of development
Figure 195: Merck & Co.: Partnering deals by therapy area
Figure 196: Merck KGaA: Dealmaking frequency 2007-2013
Figure 197: Merck KGaA: Partnering deals by type
Figure 198: Merck KGaA: Partnering deals by industry sector
Figure 199: Merck KGaA: Partnering deals by technology type
Figure 200: Merck KGaA: Partnering deals by stage of development
Figure 201: Merck KGaA: Partnering deals by therapy area
Figure 202: Mitsubishi Tanabe: Dealmaking frequency 2007-2013
Figure 203: Mitsubishi Tanabe: Partnering deals by type
Figure 204: Mitsubishi Tanabe: Partnering deals by industry sector
Figure 205: Mitsubishi Tanabe: Partnering deals by technology type
Figure 206: Mitsubishi Tanabe: Partnering deals by stage of development
Figure 207: Mitsubishi Tanabe: Partnering deals by therapy area
Figure 208: Mylan: Dealmaking frequency 2007-2013
Figure 209: Mylan: Partnering deals by type
Figure 210: Mylan: Partnering deals by industry sector
Figure 211: Mylan: Partnering deals by technology type
Figure 212: Mylan: Partnering deals by stage of development
Figure 213: Mylan: Partnering deals by therapy area
Figure 214: Novartis: Dealmaking frequency 2007-2013
Figure 215: Novartis: Partnering deals by type
Figure 216: Novartis: Partnering deals by industry sector
Figure 217: Novartis: Partnering deals by technology type
Figure 218: Novartis: Partnering deals by stage of development
Figure 219: Novartis: Partnering deals by therapy area
Figure 220: Novo Nordisk: Dealmaking frequency 2007-2013
Figure 221: Novo Nordisk: Partnering deals by type
Figure 222: Novo Nordisk: Partnering deals by industry sector

igure 223: Novo Nordisk: Partnering deals by technology type
Figure 224: Novo Nordisk: Partnering deals by stage of development
Figure 225: Novo Nordisk: Partnering deals by therapy area
Figure 226: Otsuka: Dealmaking frequency 2007-2013
Figure 227: Otsuka: Partnering deals by type
Figure 228: Otsuka: Partnering deals by industry sector
Figure 229: Otsuka: Partnering deals by technology type
Figure 230: Otsuka: Partnering deals by stage of development
Figure 231: Otsuka: Partnering deals by therapy area
Figure 232: Pfizer: Dealmaking frequency 2007-2013
Figure 233: Pfizer: Partnering deals by type
Figure 234: Pfizer: Partnering deals by industry sector
Figure 235: Pfizer: Partnering deals by technology type
Figure 236: Pfizer: Partnering deals by stage of development
Figure 237: Pfizer: Partnering deals by therapy area
Figure 238: Purdue: Dealmaking frequency 2007-2013
Figure 239: Purdue: Partnering deals by type
Figure 240: Purdue: Partnering deals by industry sector
Figure 241: Purdue: Partnering deals by technology type
Figure 242: Purdue: Partnering deals by stage of development
Figure 243: Purdue: Partnering deals by therapy area
Figure 244: Ranbaxy: Dealmaking frequency 2007-2013
Figure 245: Ranbaxy: Partnering deals by type
Figure 246: Ranbaxy: Partnering deals by industry sector
Figure 247: Ranbaxy: Partnering deals by technology type
Figure 248: Ranbaxy: Partnering deals by stage of development
Figure 249: Ranbaxy: Partnering deals by therapy area
Figure 250: Roche: Dealmaking frequency 2007-2013
Figure 251: Roche: Partnering deals by type
Figure 252: Roche: Partnering deals by industry sector
Figure 253: Roche: Partnering deals by technology type
Figure 254: Roche: Partnering deals by stage of development
Figure 255: Roche: Partnering deals by therapy area
Figure 256: Sanofi: Dealmaking frequency 2007-2013
Figure 257: Sanofi: Partnering deals by type
Figure 258: Sanofi: Partnering deals by industry sector
Figure 259: Sanofi: Partnering deals by technology type
Figure 260: Sanofi: Partnering deals by stage of development
Figure 261: Sanofi: Partnering deals by therapy area
Figure 262: Servier: Dealmaking frequency 2007-2013
Figure 263: Servier: Partnering deals by type
Figure 264: Servier: Partnering deals by industry sector
Figure 265: Servier: Partnering deals by technology type
Figure 266: Servier: Partnering deals by stage of development
Figure 267: Servier: Partnering deals by therapy area
Figure 268: Shionogi: Dealmaking frequency 2007-2013
Figure 269: Shionogi: Partnering deals by type
Figure 270: Shionogi: Partnering deals by industry sector
Figure 271: Shionogi: Partnering deals by technology type
Figure 272: Shionogi: Partnering deals by stage of development
Figure 273: Shionogi: Partnering deals by therapy area
Figure 274: Shire: Dealmaking frequency 2007-2013
Figure 275: Shire: Partnering deals by type
Figure 276: Shire: Partnering deals by industry sector
Figure 277: Shire: Partnering deals by technology type
Figure 278: Shire: Partnering deals by stage of development
Figure 279: Shire: Partnering deals by therapy area
Figure 280: Stada: Dealmaking frequency 2007-2013
Figure 281: Stada: Partnering deals by type
Figure 282: Stada: Partnering deals by industry sector

Figure 283: Stada: Partnering deals by technology type
Figure 284: Stada: Partnering deals by stage of development
Figure 285: Stada: Partnering deals by therapy area
Figure 286: Takeda: Dealmaking frequency 2007-2013
Figure 287: Takeda: Partnering deals by type
Figure 288: Takeda: Partnering deals by industry sector
Figure 289: Takeda: Partnering deals by technology type
Figure 290: Takeda: Partnering deals by stage of development
Figure 291: Takeda: Partnering deals by therapy area
Figure 292: Teva: Dealmaking frequency 2007-2013
Figure 293: Teva: Partnering deals by type
Figure 294: Teva: Partnering deals by industry sector
Figure 295: Teva: Partnering deals by technology type
Figure 296: Teva: Partnering deals by stage of development
Figure 297: Teva: Partnering deals by therapy area
Figure 298: UCB: Dealmaking frequency 2007-2013
Figure 299: UCB: Partnering deals by type
Figure 300: UCB: Partnering deals by industry sector
Figure 301: UCB: Partnering deals by technology type
Figure 302: UCB: Partnering deals by stage of development
Figure 303: UCB: Partnering deals by therapy area
Figure 304: Valeant: Dealmaking frequency 2007-2013
Figure 305: Valeant: Partnering deals by type
Figure 306: Valeant: Partnering deals by industry sector
Figure 307: Valeant: Partnering deals by technology type
Figure 308: Valeant: Partnering deals by stage of development
Figure 309: Valeant: Partnering deals by therapy area
Figure 310: Warner Chilcott: Dealmaking frequency 2007-2013
Figure 311: Warner Chilcott: Partnering deals by type
Figure 312: Warner Chilcott: Partnering deals by industry sector
Figure 313: Warner Chilcott: Partnering deals by technology type
Figure 314: Warner Chilcott: Partnering deals by stage of development
Figure 315: Warner Chilcott: Partnering deals by therapy area
Figure 328: Online partnering resources
Figure 329: Deal type definitions
Figure 330: Collaborative R&D and license agreement between GlaxoSmithKline and Supergen, November 2009

Companies Mentioned

Abbott, Actavis, Watson Pharmaceuticals, Actelion, Allergan, Amgen, Aspen Pharmacare, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, Endo Pharmaceuticals, Forest Laboratories, Galderma, Gilead Sciences, GlaxoSmithKline, Grifols, Hospira, Johnson & Johnson, Janssen, Kyowa Hakko Kirin, Lundbeck, Menarini, Merck & Co, Merck KGaA, Mitsubishi Tanabe, Mylan, Novartis, Novo Nordisk, Otsuka, Pfizer, Purdue Pharma, Roche, Sanofi, Sanofi-Aventis, Servier, Shionogi, Shire, Takeda, Teva, UCB, Valeant Pharmaceuticals, Warner Chilcott

To order this report: Partnering Deals and Alliances with Big Pharma
http://www.reportlinker.com/p01524244/Partnering-Deals-and-Alliances-with-Big-Pharma.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.